Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.39 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 4 microgram/ml (equivalent: desmopressin, qty 3.56 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - diabetes insipidus: the treatment of adh sensitive cranial diabetes insipidus, including treatment of post hypophysectomy polydipsia and polyuria.,renal concentrating capacity: by intramuscular administration to adults only, as a diagnostic test to establish renal concentrating capacity.,mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for p

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - hypertension atenolol tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. atenolol tablets usp may be administered with other antihypertensive agents. angina pectoris due to coronary atherosclerosis: atenolol is indicated for the long-term management of patients with angina pectoris. acute myocardial infarction  atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient's clinical condition allows. (see dosage and admnistration, contraindications and warnings). in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mm hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm hg) seemed less likely to benefit. atenolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). atenolol is contraindicated in those patients with a history of hypersensitivity to the atenolol or any of the drug product's components

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration and perforation ). diclofenac sodium delayed-release tablets are indicated: diclofenac sodium delayed-release tablets are contraindicated in the following patients.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: conjunctivitis: gram-positive bacteria: gram-negative bacteria:      staphylococcus aureus      enterobacter cloacae      staphylococcus epidermidis      haemophilus influenzae      streptococcus pneumoniae      proteus mirabilis      pseudomonas aeruginosa corneal ulcers: gram-positive bacteria: gram-negative bacteria:      staphylococcus aureus      pseudomonas aeruginosa      staphylococcus epidermidis      serratia marcescens*      streptococcus pneumoniae anaerobic species:      propionibacterium acnes * efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: conjunctivitis: gram-positive bacteria: gram-negative bacteria:      staphylococcus aureus      enterobacter cloacae      staphylococcus epidermidis      haemophilus influenzae      streptococcus pneumoniae      proteus mirabilis      pseudomonas aeruginosa corneal ulcers: gram-positive bacteria: gram-negative bacteria:      staphylococcus aureus      pseudomonas aeruginosa      staphylococcus epidermidis      serratia marcescens*      streptococcus pneumoniae anaerobic species:       propionibacterium acnes * efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warnings).

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - attention deficit disorders, narcolepsy attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous syst

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: * efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: * efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see warning).